However, the response rate to the checkpoint inhibitor nivolumab (PD-1 monoclonal antibody) for HCC is 15–20% [77], and a randomized controlled multicenter trial found no difference in treatment with nivolumab compared with sorafenib (recommended first-line chemotherapeutic drug for HCC) [78]. Here, PDCD1 is linked to hepatocellular carcinoma.